

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:*  
Gregory Anderson, M.S., M.P.H.,  
Scientific Review Officer, CDC, National  
Center for HIV, Viral Hepatitis, STD,  
and TB Prevention, 1600 Clifton Road  
NE, Mailstop US8-1, Atlanta, Georgia  
30329-4027, Telephone: (404) 718-  
8833; Email: [GAnderson@cdc.gov](mailto:GAnderson@cdc.gov).

The Director, Strategic Business  
Initiatives Unit, Office of the Chief  
Operating Officer, Centers for Disease  
Control and Prevention, has been  
delegated the authority to sign **Federal  
Register** notices pertaining to  
announcements of meetings and other  
committee management activities, for  
both the Centers for Disease Control and  
Prevention and the Agency for Toxic  
Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit,  
Office of the Chief Operating Officer, Centers  
for Disease Control and Prevention.*

[FR Doc. 2022-07246 Filed 4-5-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**Centers for Disease Control and  
Prevention**

**Disease, Disability, and Injury  
Prevention and Control Special  
Emphasis Panel (SEP)—RFA-CE22-  
012, The CDC National Centers of  
Excellence in Youth Violence  
Prevention (YVPCs): Rigorous  
Evaluation of Prevention Strategies To  
Prevent and Reduce Community Rates  
of Youth Violence; Cancellation of  
Meeting**

**AGENCY:** Centers for Disease Control and  
Prevention, Department of Health and  
Human Services

**ACTION:** Notice.

**FOR FURTHER INFORMATION CONTACT:**

Aisha L. Wilkes, M.P.H., Scientific  
Review Officer, National Center for  
Injury Prevention and Control, CDC,  
4770 Buford Highway NE, Mailstop  
S106-9, Atlanta, Georgia 30341-3717,  
Telephone: (404) 639-6473, Email:  
[AWilkes@cdc.gov](mailto:AWilkes@cdc.gov).

**SUPPLEMENTARY INFORMATION:** Notice is  
hereby given of a change in the meeting  
of the Disease, Disability, and Injury  
Prevention and Control Special  
Emphasis Panel—RFA-CE22-012, The  
CDC National Centers of Excellence in  
Youth Violence Prevention (YVPCs):  
Rigorous Evaluation of Prevention  
Strategies to Prevent and Reduce  
Community Rates of Youth Violence;

June 21-22, 2022, 8:30 a.m.–5:30 p.m.,  
EDT.

The web conference was published in  
the **Federal Register** on February 1,  
2022, Volume 87, Number 21, page  
5482.

This meeting is being canceled in its  
entirety.

The Director, Strategic Business  
Initiatives Unit, Office of the Chief  
Operating Officer, Centers for Disease  
Control and Prevention, has been  
delegated the authority to sign **Federal  
Register** notices pertaining to  
announcements of meetings and other  
committee management activities, for  
both the Centers for Disease Control and  
Prevention and the Agency for Toxic  
Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit,  
Office of the Chief Operating Officer, Centers  
for Disease Control and Prevention.*

[FR Doc. 2022-07243 Filed 4-5-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**Centers for Disease Control and  
Prevention**

[Docket No. CDC-2022-0046]

**Advisory Committee to the Director  
(ACD), Centers for Disease Control and  
Prevention (CDC)**

**AGENCY:** Centers for Disease Control and  
Prevention (CDC), Department of Health  
and Human Services (HHS).

**ACTION:** Notice of meeting and request  
for comment.

**SUMMARY:** In accordance with the  
Federal Advisory Committee Act, the  
CDC announces the following meeting  
for the Advisory Committee to the  
Director, Centers for Disease Control  
and Prevention (ACD, CDC). This  
meeting is open to the public. Time will  
be available for public comment. The  
meeting will be webcast live via the  
World Wide Web.

**DATES:** The meeting will be held on May  
3, 2022, from 11:00 a.m. to 4:00 p.m.,  
EDT (times subject to change). The  
public may submit written comments  
from April 6, 2022 through April 28,  
2022.

**ADDRESSES:** You may submit comments  
identified by Docket No. CDC-2022-  
0046 by any of the following methods:

- *Federal eRulemaking Portal:*  
<https://www.regulations.gov>. Follow the  
instructions for submitting comments.
- *Mail:* Kerry Caudwell, MPA,  
Centers for Disease Control and

Prevention, 1600 Clifton Road NE, MS  
H21-10, Atlanta, Georgia 30329-4027.  
Attn: Docket No. CDC-2022-0046.

*Instructions:* All submissions received  
must include the Agency name and  
Docket Number. All relevant comments  
received in conformance with the  
<https://www.regulations.gov> suitability  
policy will be posted without change to  
<https://www.regulations.gov>, including  
any personal information provided. For  
access to the docket to read background  
documents or comments received, go to  
<https://www.regulations.gov>.

Written public comments submitted  
up to 72 hours prior to the ACD meeting  
will be provided to ACD members  
before the meeting.

Written comments received in  
advance of the meeting will be included  
in the official record of the meeting.

**FOR FURTHER INFORMATION CONTACT:**

Kerry Caudwell, MPA, Centers for  
Disease Control and Prevention, Office  
of the Chief of Staff, 1600 Clifton Road  
NE, MS H21-10, Atlanta, Georgia  
30329-4027, Telephone: (404) 639-  
7000; Email Address: [ACDDirector@cdc.gov](mailto:ACDDirector@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* The Advisory Committee to  
the Director (ACD), CDC, shall advise  
the Secretary, HHS, and the Director,  
CDC, on policy and broad strategies that  
will enable CDC to fulfill its mission of  
protecting health through health  
promotion, prevention, and  
preparedness. The committee  
recommends ways to prioritize CDC's  
activities, improve results, and address  
health disparities. It also provides  
guidance to help CDC work more  
effectively with its various private and  
public sector constituents to make  
health protection a practical reality.

*Matters to be Considered:* The agenda  
will include discussions regarding  
CDC's current and future work in the  
following topic areas: (1) Data  
modernization; (2) laboratory quality;  
and (3) health equity. The Advisory  
Committee to the Director (ACD) will  
consider the formation of working  
groups for each of the first two topics  
and hear a report from the existing  
health equity working group on the  
third topic. Agenda items are subject to  
change as priorities dictate.

**Public Participation**

Interested persons or organizations  
are invited to participate by submitting  
written views, recommendations, and  
data. Please note that comments  
received, including attachments and  
other supporting materials, are part of  
the public record and are subject to  
public disclosure. Comments will be

posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

*Written Public Comment:* The docket will be opened to receive written comments on April 6, 2022 through April 28, 2022.

*Oral Public Comment:* This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

*Procedure for Oral Public Comment:* All persons interested in making an oral public comment at the May 3, 2022, ACD meeting must submit a request by visiting <https://www.cdc.gov/about/advisory-committee-director/> no later than 11:59 p.m., EDT, April 22, 2022, according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by April 26, 2022. To accommodate the significant interest in participation in the oral public comment session of ACD meetings, each speaker will be limited to 2 minutes, and each speaker may only speak once per meeting.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-07247 Filed 4-5-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA—OH-22-002, Panel B and Panel D, NIOSH Centers for Agricultural Safety and Health.

*Dates and Times:* May 9–10, 2022, Panel B, 11:00 a.m.–6:00 p.m., EDT; and May 11–12, 2022, Panel D, 11:00 a.m.–6:00 p.m., EDT.

*Place:* Video-Assisted Meeting.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Dan Hartley, Ed.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, West Virginia 26505, Telephone: (304) 285-5812; Email: [DHartley@cdc.gov](mailto:DHartley@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for

both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-07245 Filed 4-5-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Clinical Laboratory Improvement Advisory Committee (CLIAC); Notice of Charter Renewal**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of charter renewal.

**SUMMARY:** This gives notice under the Federal Advisory Committee Act of October 6, 1972, that the Clinical Laboratory Improvement Advisory Committee (CLIAC), Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through February 19, 2024.

**FOR FURTHER INFORMATION CONTACT:** Reynolds M. Salerno, Ph.D., Designated Federal Officer, Clinical Laboratory Improvement Advisory Committee (CLIAC), Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia 30329-4027, Telephone: (404) 498-6516; Email: [RSalerno@cdc.gov](mailto:RSalerno@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-07240 Filed 4-5-22; 8:45 am]

**BILLING CODE 4163-18-P**